Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors

PD‐1/PD‐L1 (programmed cell death‐1 and programmed death‐ligand 1) inhibitors utilization in neoadjuvant therapy has been assessed in tumors. This study focused on the clinical benefits of neoadjuvant anti‐PD‐1/PD‐L1 therapy. A comprehensive search was conducted in electronic databases to identify e...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhiyang, Wu, Xin, Zhao, Yanjie, Xiao, Yinan, Zhao, Yunuo, Zhang, Ting, Li, Hui, Sha, Fushen, Wang, Yating, Deng, Lei, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491227/
https://www.ncbi.nlm.nih.gov/pubmed/34766136
http://dx.doi.org/10.1002/mco2.61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491227/
https://www.ncbi.nlm.nih.gov/pubmed/34766136
http://dx.doi.org/10.1002/mco2.61

Ejemplares similares